Literature DB >> 17410330

Metabolic deactivation of low-grade glioma during chemotherapy.

Ulrich Roelcke, Matthias Wyss, Esther Bärtschi, Silvia Hofer.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17410330     DOI： 10.1007/s00415-006-0321-x

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  8 in total

1.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

Authors:  D Hanahan; G Bergers; E Bergsland
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo.

Authors:  P Heiss; S Mayer; M Herz; H J Wester; M Schwaiger; R Senekowitsch-Schmidtke
Journal:  J Nucl Med       Date:  1999-08       Impact factor: 10.057

3.  Diagnostic value of the fast-FLAIR sequence in MR imaging of intracranial tumors.

Authors:  H W Husstedt; M Sickert; H Köstler; B Haubitz; H Becker
Journal:  Eur Radiol       Date:  2000       Impact factor: 5.315

4.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

5.  "Facilitated" amino acid transport is upregulated in brain tumors.

Authors:  T Miyagawa; T Oku; H Uehara; R Desai; B Beattie; J Tjuvajev; R Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1998-05       Impact factor: 6.200

6.  O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours.

Authors:  M Weckesser; K J Langen; C H Rickert; S Kloska; R Straeter; K Hamacher; G Kurlemann; H Wassmann; H H Coenen; O Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-14       Impact factor: 9.236

7.  Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.

Authors:  M Brada; L Viviers; C Abson; F Hines; J Britton; S Ashley; S Sardell; D Traish; A Gonsalves; P Wilkins; C Westbury
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

8.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.

Authors:  K Hoang-Xuan; L Capelle; M Kujas; S Taillibert; H Duffau; J Lejeune; M Polivka; E Crinière; Y Marie; K Mokhtari; A F Carpentier; F Laigle; J M Simon; P Cornu; P Broët; M Sanson; J Y Delattre
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544
  8 in total
  1 in total

Review 1.  Current concepts in the evaluation and management of WHO grade II gliomas.

Authors:  Joseph M Piepmeier
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.